Trav4n-4 inhibitors represent a specific class of chemical compounds that interact with the Trav4n-4 protein or receptor, inhibiting its biological activity through targeted molecular interactions. These inhibitors are designed to bind to either the active site or an allosteric site of Trav4n-4, thereby blocking its normal function or altering its structural conformation. The binding process typically involves non-covalent interactions such as hydrogen bonding, van der Waals forces, electrostatic interactions, and hydrophobic contacts, all of which contribute to the overall stability of the inhibitor-protein complex. Depending on the nature of the Trav4n-4 protein, these inhibitors may act as competitive inhibitors, directly competing with natural substrates for the active site, or as allosteric modulators, inducing changes in the protein's shape that reduce its functional activity.
The structural diversity of Trav4n-4 inhibitors allows for a wide range of chemical designs, from small organic molecules to larger, more complex entities such as peptides or macrocycles. Key structural features often include aromatic rings, heteroatoms such as nitrogen or sulfur, and various functional groups like hydroxyl, amine, or carboxyl groups, which facilitate specific interactions with the binding pockets of Trav4n-4. These inhibitors are also characterized by their physicochemical properties, such as molecular weight, lipophilicity, and polarity, which influence their solubility, stability, and binding affinity. The balance between hydrophobic and hydrophilic regions in the inhibitor molecule is critical for optimizing its interaction with Trav4n-4, ensuring that it can bind effectively under physiological conditions. Inhibitor design often involves modifying these features to enhance selectivity and reduce off-target interactions, providing a high degree of specificity for the Trav4n-4 target.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Inhibits protein kinase C (PKC), which is involved in signaling pathways that Trav4n-4 may be a part of, leading to reduced activity of Trav4n-4 through decreased phosphorylation events that are critical for its function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Selectively inhibits Src family kinases, which could be upstream of Trav4n-4, resulting in decreased activation of downstream targets including Trav4n-4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, which is involved in the Akt signaling pathway; inhibition of PI3K leads to reduced Akt activity, potentially reducing Trav4n-4 activity as Akt can regulate a wide range of proteins including Trav4n-4. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which is part of the MAPK/ERK pathway; by inhibiting MEK, the subsequent activation of ERK is prevented, which could lead to decreased activation of Trav4n-4 if it is regulated by the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits c-Jun N-terminal kinase (JNK), which may influence Trav4n-4 activity by altering the phosphorylation status of proteins that interact with or regulate Trav4n-4. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAP kinase inhibitor that could inhibit the p38 signaling pathway, thereby potentially reducing Trav4n-4 activity if Trav4n-4 is regulated via this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Selectively inhibits MEK1/2, preventing the activation of the MAPK/ERK pathway, and potentially inhibiting Trav4n-4 activity if it is dependent on signals from this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent inhibitor of PI3K like LY294002; Wortmannin's inhibition of PI3K would lead to a decrease in Akt activity, which may result in decreased Trav4n-4 activity if PI3K/Akt is a regulatory pathway for Trav4n-4. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which is a key regulator of cell growth and proliferation; by inhibiting mTOR, the function of proteins downstream or regulated by mTOR, which could include Trav4n-4, is decreased. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A pan-PKC inhibitor that can inhibit multiple PKC isoforms, potentially reducing the phosphorylation and activity of Trav4n-4 if it is regulated by PKC-dependent signaling. | ||||||